logo-loader

Investor Update: Cello Health puts in strong first half performance

Top stories from the Proactive Investors UK newsroom.

Healthcare marketing group Cello Health (LON:CLL) has reported a strong first six months of the year, with good like-for-like growth in overall net revenues and headline profit before tax. Margins have also improved and this year’s results will at least be in line with current market expectations.

Minds + Machines (LON:MMX) has also seen healthy revenue growth with domain name registrations up 19% to 1.82mln. Sales of the group’s original 28 domains rose by 30%.

OptiBiotix (LON:OPTI) has signed a distribution agreement with BioEnergiser that will see its SlimBiome Medical weight loss supplements sold online in the UK. Today’s deal gives BioEnergiser the right to distribute the supplements online within the UK, whilst still allowing Opti to continue to sell its product on its own online store.

Online fashion retailer ASOS has warned sales growth is being held back by  problems in the US with its new warehouse. Sales in the four months rose by 12% but ASOS says the US problem will continue for the rest of the year and is scaling back expectations accordingly. 

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

'The clinical benefits of Clevegen have now been demonstrated' Faron Pharma CEO

Faron Pharmaceuticals Oy's (LON:FARN) Markku Jalkanen caught up with Proactive London's Andrew Scott to discuss the recently released Matins trial update which is assessing the firm's drug Clevegen. He says feedback from the dose escalation study confirmed Clevegen has good tolerability...

7 minutes ago

2 min read